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Abstract L-PGDS is the most abundant protein present in
the cerebrospinal fluid (CSF). Although CSF was believed to
be homogenous in content, a previous study has showed that
a marked concentration gradient of L-PGDS exists between
the spinal CSF and the CSF in the subarachnoid space of
patients with optic nerve disease (papilledema and normal-
tension glaucoma). Astrocytes play a critical role in main-
taining the integrity of axon function in the central nervous
system and specifically in the optic nerve, and we therefore
investigated the biochemical effects of L-PGDS on the
proliferation of astrocytes and on the production of adeno-
sine triphosphate (ATP) by astrocyte mitochondria. We
found an inhibitory effect of L-PGDS on both proliferation
of astrocytes and production of astrocyte ATP. The concen-
trations that inhibited astrocyte proliferation and ATP
production were in the range measured in patients with
idiopathic intracranial hypertension and in patients with
normal-tension glaucoma. As the CSF is in contact with
axons and mitochondria of the optic nerve (Bristow et al.
Archives of Ophthalmology, 120, 791–796, 2002), we pos-
tulate that a change in the concentration of CSF protein such
as L-PGDS could exercise a harmful effect on these structures.
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Introduction
L-PGDS, also called betatrace protein, is a prostaglandin
synthase that consists of 165 amino acid sequences, has a
molecular weight of 25 kDa, and catalyzes the isomeriza-
tion of the 9, 11-endoperoxide group of PGH2, a precursor
of various protanoids, to produce PGD2 with 9-hydroxy and
11-keto groups (Clausen 1961; Hoffmann et al. 1993, 1996;
Urade and Hayaishi 2000a, b). Although L-PGDS is
present in very low concentrations in the serum, it is the
most abundant polypeptide synthesized intrathecally (Pohl
et al. 1997; Urade and Hayaishi 2000a). Normal values for
L-PGDS in the cerebrospinal fluid (CSF) of healthy persons
range from 13.4 to 18.4 mg/L, with a slight increase in
concentration with increasing age (Link and Olsson 1972;
Tumani et al. 1998; Reiber et al. 2003).
L-PGDS mRNAwas first detected in mesenchymal cells
destined to become leptomeninges and in developing testis
(Tokugawa et al. 1998). Immunoreactivity and mRNA for
L-PGDS were subsequently identified in meningoepithelial
cells, arachnoid trabecular cells, and arachnoid pia mater
cells as well as in oligodendrocytes and astrocytes (Urade et
al. 1993; Blödorn et al. 1999; Beuckmann et al. 2000;
Urade and Hayaishi 2000a, b), and it eventually became
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clear that L-PGDS is localized primarily in the central
nervous system (CNS) and related organs, such as the
cochlea and the eye (e.g., in the pigment and ciliary body
epithelium) (Goh et al. 1987), where the production and
secretion of L-PGDS has been demonstrated in cultured
astrocytes, leptomeningeal cells, and choroid plexus epi-
thelium (Giacomelli et al. 1996).
L-PGDS belongs to the family of lipocalins, a group of
proteins responsible for binding and transporting small
lipophilic molecules, such as bilirubin, biliverdin, retinol,
and sexual pheromones (Beuckmann et al. 2000; Urade and
Hayaishi 2000a). L-PGDS concentration in rat CSF shows a
circadian change coupled to the sleep rhythm, with the concen-
tration increasing with increased sleep (Hayaishi et al. 1991).
Some of the functions of L-PGDS seem contradictory.
Specifically, although increased L-PGDS activity appears to
correlate with apoptosis of PC12 neuronal cells as well as
phorbol 12-myristate, 13-acetate (PMA)-induced apoptosis
(Ragolia et al. 2001, 2003), upregulated L-PGDS also has
been demonstrated in αβ-crystallin-positive oligodendrocytes
and astrocytes in patients with chronic multiple sclerosis in
whom it is believed to play a role in neuroprotection
(Kagitani-Shimono et al. 2006). In addition, in an animal
model, Liang et al (2005) described a neuroprotective effect
of hippocampal neurons via PGD2 (L-PGDS) mediated by
the DP1 receptor. Elevated concentrations of betatrace protein
in CSF have been found in patients with acute exacerbations
of multiple sclerosis (Link and Olsson 1972). Upregulation of
L-PGDS was also demonstrated in oligodendrocytes after
hypoxic–ischemic injury in developing brains in mouse
models and in the brains of patients with multiple sclerosis
(Taniguchi et al. 2007a). Based on these findings, Taniguchi
and colleagues (Taniguchi et al. 2007a, b) suggest that
L-PGDS may function as an early stress protein with
immunomodulatory and neuroprotective activity. These find-
ings may explain the fact that high levels of L-PGDS are
present in the subarachnoid space (SAS) of the optic nerve in
patients with idiopathic intracranial hypertension (IIH) and
normal-tension glaucoma (NTG) (Killer et al. 2006, 2007). In
addition, a marked concentration gradient of L-PGDS exists
between the spinal CSF and the CSF in the SAS of the optic
nerves in such patients (Killer et al. 2006, 2007). At issue is
whether the findings are related to the development of these
conditions or simply represent an epiphenomena, i.e., is there
a biological effect of L-PGDS that could account for either
the development of the conditions or the optic nerve damage
that occurs from them? As astrocyte function and adenosine
triphosphate (ATP) production are important for axonal
function, especially for white-matter axonal regeneration
(Tom et al., 2004; Butt et al. 2004), we investigated the
biochemical effects of L-PGDS on the proliferation of
astrocytes and on the production of ATP by astrocyte
mitochondria in vitro.
Materials and Methods
Cell Culture and Treatment with L-PGDS
The astrocyte cell line LN 229 (courtesy of Dr. Stephan
Frank, Department of Pathology, University of Basel,
Switzerland) was grown in 75-cm2 flasks (Sarstedt, USA)
and cultured in Quantum 263 medium (PAA Biologics
GmbH, Cöllbe, Germany) with penicillin/streptomycin
(100 U/mL, 100 µg/mL; Sigma, Germany) until conflu-
ence. Cells were washed with phosphate-buffered saline
(PBS) (Sigma) and trypsinized. Supernatant was removed
after centrifugation, and cell suspension was added to six-
well plates (Falcon, USA) pre-coated with collagen
(Sigma), with each well containing 2×104 cells. The
medium was replaced by fresh culture medium containing
human L-PGDS (courtesy of Prof. H.S. Conradt; Glyco-
Thera GmbH, Feodor-Lynen-Straße 35, 30625 Hannover,
Niedersachsen, Germany) with series concentration (7, 14,
35, 70, 140 µg/mL) or no agonist (0 as control).
Proliferation Assay
After incubation with L-PGDS for 72 h, cells were washed
with PBS without Ca2+ or Mg2+ and then harvested. Cell
number, cell diameter, and cell volume were determined by a
cell analyzer system CASY1 (Schaerfe System, Reutlingen,
Germany). Samples of suspended cells (100 μL) were diluted
in 10 mL isotonic CASY solution (7.93 mg/mL NaCl,
0.38 mg/mL Na2EDTA, 0.4 mg/mL KCl, 0.22 mg/mL
NaH2PO4·H2O, 2.45 mg/mL Na2HPO·2H2O, 0.3 mg/mL
NaF; Schaerfe System). During the measurement, a current
was supplied to the capillary via two platinum electrodes
giving a defined electrical resistance. Thus, while passing the
capillary, the cells generated electrical signals and could be
scanned, providing data regarding cell number, diameter, and
volume (Stadlmann et al. 2006).
ATP Determination
Fifty thousand cells per well were seeded into 12-well
plates (Falcon, USA), cultured with Quantum 263 medium
containing L-PGDS 70 µg/mL or 10% PBS for 1 and
2 days, respectively. Culture medium was removed and
ATP incubation medium (KCL 15 mM, Tris–HCl 25 mM,
EDTA 0.2 mM, KH2PO4 1 mM, pH 7.4, 1% albumin, ADP
1 mM) with or without pyruvate 100 mM and malate
100 mM was added, and the cells were incubated at 37°C
for 2 h. After incubation medium was withdrawn and cells
were washed with PBS, incubation medium without ADP
was added, and the cells were detached with a cell scraper.
Cell supernatant was collected into a micro test tube, boiled
with Tris–EDTA, and centrifuged at 1,000×g at room
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temperature for 1 min. The supernatant was then collected
for protein and ATP assay.
The total protein concentration in each sample was
analyzed by Bradford protein (BIO-RAD, Germany) assay
with a spectrophotometer (Spectra MAX 190, Bucher
Biotec, USA). Samples were placed in a 96-well plate
(Costar, USA), and BSA protein (Sigma, USA) with series
concentration (0–0.2 mg/mL) was utilized as the standard to
normalize the assay. Optical absorption at 595 nm was
measured. The quantity of ATP was measured by using an
ATP determination kit (A-22066, Eugene, OR, USA)
following the manufacturer’s instructions. The reagents and
reaction mixture were combined according to the protocol by
molecular probes. Two microliters of the sample and 198 μL
of the reagent of the ATP determination kit were placed into
96-well assay microplates and reacted to quantify ATP
production. Luminescence was measured using a luminom-
eter (Berthold Technologies GmbH, Switzerland), and ATP
production was quantified using a standard curve from 0 to
50 μM. ATP production was expressed as μM/μg mitochon-
drial protein (Drew and Leeuwenburgh 2003).
Statistical Analysis
For astrocyte proliferation analysis, one-way analysis of
variance followed by post hoc comparisons of the group
means according to the method of Bonferroni was used. For
ATP determination, data were analyzed with three-way
analysis of variance, and the Student’s t test was performed
to ascertain the statistical significance between two experi-
ments treated with the same reagent at different times.
Statistical analyses were conducted with SPSS 10.0
statistical analysis software (SPSS Inc., Chicago, IL,
USA), with data presented as mean ± SD. Values of
p <0.05 were considered significant.
Results
Inhibition of Proliferation of Astrocytes
Incubation of astrocytes with L-PGDS for 72 h resulted in an
inhibition of cellular proliferation that correlated with the
concentration of L-PGDS (Fig. 1). Specifically, treatment of
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Fig. 1 Effect of L-PGDS on astrocytes proliferation. Proliferation of
astrocytes decreased with an increase of the concentration of L-PGDS.
Evident decrease of cell number was detected at L-PGDS concentra-
tion ranging from 14 to 140 µg/mL. Results are mean ± SD of six
experiments. Statistically different data are indicated by asterisks, **
represent p<0.005 compared with controls
Fig. 2 Effect of L-PGDS on
proliferation of astrocytes. a
Astrocytes of controls after the
incubation for 1 day. b Astro-
cytes treated with L-PGDS
(70 µg/mL) after incubation for
1 day. c Obvious proliferation of
astrocytes of controls is observed
after incubation for 3 days. d
Number of astrocytes treated
with L-PGDS (70 µg/mL) after
incubation for 3 days is much
less than that of controls incu-
bated for the same period (×10)
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astrocytes with L-PGDS at a dose of 14 µg/mL resulted in a
decrease in cell number (73,573±18,600) compared with
controls (135,970±52,480; p<0.005), with the number of
cells decreasing with increasing concentrations of L-PGDS
of 70 and 140 µg/mL. In our cultures, L-PGDS produced its
maximal inhibitory effect at a dose of 140 µg/mL, resulting
in a cell number of 21,890±7,910 (p<0.005), decreased six-
fold compared with controls. As shown in Fig. 2, astrocytes
from controls showed extensive proliferation after an
incubation time of 3 days compared with those incubated
for 1 day (Fig. 2a, c); the proliferation of cells treated with
L-PGDS at a dose of 70 µg/mL, however, was inhibited
(Fig. 2b, d). The diameter of astrocytes after treatment with
L-PGDS as determined by CASY I decreased from 18.445±
0.353 to 18.007±0.473 µm with concentrations of L-PGDS
ranging from 7 to 140 µg/mL, with the maximum reduction
(18.007±0.473 µm, p=0.625) occurring with a dose of
140 µg/mL. There was no significant difference in astrocyte
mean cell volume with increasing concentrations of L-PGDS
compared with controls (3,792±319 fL to 3,661±326 fL vs.
3,849±528 fL; p=0.93) (Table 1).
Effect of L-PGDS on ATP Production
Cellular ATP production was measured after astrocytes were
treated with PBS (controls), L-PGDS, mitochondrial com-
plex I substrates (pyruvate + malate), or L-PGDS plus
substrates for 1 and 2 days. After 1 day, there was an
increase in ATP production in cells incubated with either
PBS or substrate without L-PGDS compared with cells
treated with L-PGDS; however, none of the changes in ATP
production with substrate (1.135±0.582 μM/mg protein),
L-PGDS (0.698±0.246 μM/mg protein), or L-PGDS plus
substrate (0.914±0.547 μM/mg protein) were significantly
different from controls (0.972±0.396 μM/mg protein, p>
0.05) (Fig. 3). After 2 days of incubation with either PBS or
substrate alone, ATP production was unchanged compared
with ATP production after 1 day of incubation (Fig. 3),
whereas cells treated with L-PGDS with or without substrate
showed a marked decrease in ATP production (0.056±0.019,
0.074±0.036 μM/mg protein, respectively) compared with
cells incubated with PBS (0.492±0.099 μM/mg protein) or
substrate alone (0.633±0.159 μM/mg protein) for the same
length of time (p<0.01), indicating an inhibitory effect by
L-PGDS. In addition, cells incubated with L-PGDS for
2 days showed significantly reduced ATP production
compared with cells incubated with L-PGDS for 1 day (p<
0.05) (Fig. 3). The effect of L-PGDS and of incubation time
on ATP production was highly significant (p=0.002, p<
0.001, respectively).
Discussion
In this study, we report that L-PGDS inhibits the prolifer-
ation of astrocytes in cell culture, with the degree of
inhibition correlating with the concentration of L-PGDS. In
addition, astrocytes incubated with L-PGDS show reduced
ATP production, with the amount of reduction increasing
with an increased incubation time. Thus, it appears that
L-PGDS suppresses mitochondrial function in astrocytes
regardless of the availability of mitochondrial complex I
substrates malate and pyruvate.
The decline of the astrocyte cell number correlates with
an increase of L-PGDS concentration and also with an
increased time of incubation, particularly when the
L-PGDS concentration exceeds the maximum normal
physiological concentration 140 µg/mL (Fig. 1). Indeed,
when astrocytes are incubated with L-PGDS in a concen-
L-PGDS concentration (µg/mL) Cell number (104) Cell diameter (µm) Cell volume (103fL)
0 13.597±5.248 18.635±0.608 3.849±0.528
7 9.320±3.051 18.445±0.353 3.707±0.217
14 7.357±1.860 18.343±0.281 3.639±0.171
35 3.042±0.860 18.297±0.550 3.792±0.319
70 2.490±0.630 18.327±0.685 3.661±0.326
140 2.189±0.791 18.007±0.473 3.693±0.581
Table 1 Cell number, diameter,
and volume of astrocytes (LN
229) incubated with L-PGDS as
determined by CASY
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Fig. 3 Effect of L-PGDS on ATP production of astrocytes. L-PGDS
(70 µg/mL) showed an inhibitory effect on ATP production after
incubation for 2 days. Data are represented as mean ± SD of four
independent experiments. *p<0.05; **p<0.01
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tration of 70 µg/mL (a concentration found in the CSF of
the subarachnoid space of the optic nerve in some patients
with IIH (Killer et al. 2007)), there is a significant reduction
of ATP production after 2 days of incubation (Fig. 3).
It is clear from our study that L-PGDS both inhibits
proliferation of astrocytes and reduces production of ATP
by these cells. The mechanism for these effects is not
known and there are several possible mechanisms by which
these effects could occur. For example, L-PGDS has the
potential to uncouple the oxidative phosphorylation chain
in mitochondria (Kanekiyo et al. 2007), thus decreasing
ATP production. This, in turn, could lead to reduced growth
of astrocytes. Such an effect might be enhanced by the
chaperone activity of L-PGDS (Kanekiyo et al. 2007). In a
recent article, Xiang et al. (2007) reported that PGD2 and
15d-PGJ2 induced apoptosis of undifferentiated oligoden-
drocytes. L-PGDS is involved in the enzymatic process
producing these molecules and thus might play a role in the
process of myelin damage.
Astrocytes are among the most robust cells in the CNS.
The inhibition of their proliferation by L-PGDS reflects the
high biological activity of this substance. Thus, it seems
possible that less robust structures such as the axons and
their myelin sheaths might be even more susceptible to
damage caused by elevated L-PGDS concentrations. Final-
ly, high concentrations of L-PGDS might also be toxic to
the astrocytes.
Regardless of the mechanism by which L-PGDS inhibits
astrocyte metabolism and growth, our findings are consis-
tent with the results of other investigators that suggest a role
for this substance in neurological and ocular disorders that
involve glial–neuronal interactions. For example, Kanekiyo
et al. found evidence that L-PGDS may act as a major
endogenous Aβ chaperone in the brain and may have a role
in the pathogenesis of Alzheimer’s disease (Kanekiyo et al.
2007).
In summary, this report describes a significant inhibitory
effect of L-PGDS on both proliferation and ATP production
of astrocytes in vitro. The concentrations used for treating
astrocyte cultures in this study are in the range of
concentrations measured in patients with disorders that are
associated with optic nerve damage, such as IIH and NTG.
The pathophysiology of NTG is not yet fully understood;
neither is vision loss in patients with IIH. Further studies
that evaluate the effect of L-PGDS on glial cells in the optic
nerve are needed to define the role of elevated L-PGDS
concentration in optic nerve disease.
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